News - Roche, Genentech

Filter

Current filters:

RocheGenentech

Popular Filters

1 to 25 of 51 results

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

US FDA clears Xolair for chronic idiopathic urticaria

23-03-2014

Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

03-03-2014

An independent data monitoring committee has recommended that Swiss drug major Roche’s Phase III METLung…

BiotechnologyGenentechonartuzumabOncologyResearchRoche

PDL BioPharma settles litigation with Genentech and Roche

03-02-2014

US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL

04-11-2013

The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA

22-10-2013

Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production

14-10-2013

Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

FDA advisory panel backs new indication for Genentech's Perjeta

13-09-2013

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

Conditional EU approval for Roche basal cell carcinoma drug

15-07-2013

The European Commission has granted conditional approval to Swiss drug major Roche's (ROG: SIX) Erivedge…

BiotechnologyCurisErivedgeEuropeGenentechOncologyPharmaceuticalRegulationRoche

Immunocore and Genentech collaborate to develop ImmTACs for multiple cancer targets

01-07-2013

Immunocore, an Oxford, UK-based biotechnology company developing novel biological drugs known as ImmTACs…

BiotechnologyGenentechLicensingOncologyResearchRoche

PDL files for arbitration for alleged royalties underpayments by Genentech

11-06-2013

USA-based PDL BioPharma (Nasdaq: PDLI) revealed today (June 11) that it has filed a Notice of Arbitration…

BiotechnologyFinancialGenentechLegalPDL BioPharmaPharmaceuticalRoche

Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma

03-06-2013

Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…

AvastinBiotechnologyGenentechOncologyPharmaceuticalResearchRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Strong initial data on Genentech's obinutuzumab in most common blood cancer

16-05-2013

Genentech, the biotech subsidiary of Swiss drug major Roche Group (ROG: SIX), has announced positive…

BiotechnologyGA101GenentechobinutuzumabOncologyResearchRoche

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

US FDA approves Roche's late-stage breast cancer drug Kadcyla

25-02-2013

The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Genentech enters $111 million drug discovery pact with RQx Pharma

13-02-2013

California, USA-based privately-held RQx Pharmaceuticals said yesterday that it has entered into a drug…

BiotechnologyGenentechLicensingRocheRQx Pharmaceuticals

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

San Antonio breast cancer meeting highlights

10-12-2012

There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…

AvastinBiotechnologyEisaiGenentechHerceptinOncologyPerjetaPharmaceuticalResearchRoche

Curis in-licenses cancer candidate from Genentech

30-11-2012

US drug development firm Curis (Nasdaq: CRIS) that it has licensed from Genentech, a subsidiary of Swiss…

BiotechnologyCurisGDC-0917GenentechGUDC-427LicensingOncologyPharmaceuticalRoche

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

1 to 25 of 51 results

Back to top